Navigation Links
Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
Date:2/5/2009

CALGARY, Feb. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 7th Annual BioPartnering North America Conference on Monday, February 9, 2009 at 4:30 p.m. PST. The event will be held at the Westin Bayshore Resort in Vancouver, B.C. from February 8-10, 2009.

About BioPartnering North America

Now in its seventh year, BioPartnering North America (BPN) offers excellent partnering opportunities for lifescience innovators and investors. Hosted by LifeSciences British Columbia, BIOTECanada, and BioAlberta, BPN annually attracts senior business development executives from around the globe. BPN offers a targeted approach to the best lifescience partnering opportunities.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Capture of nanomagnetic fingerprints a boost for next-generation information storage media
2. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
3. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
4. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
5. BodyMedia, Inc. Launches GowearFit, the First Direct-to-Consumer Lifestyle and Calorie Management System
6. Media Advisory - Atlantica BioEnergy Task Force Leaders Roundtable
7. Media Alert From Residual Risk Reduction Initiative (R3i): 19:00 CST Sunday 9 November 2008
8. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
10. Progress toward new storage media
11. Edmonton's Technology Community: Using Social Media to Raise Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... Feb. 4, 2016 Beike Biotechnology, the ... institutions attended a ceremony in late 2015 to mark ... therapy in 2016. --> ... Platform for Personalized Cell Therapy" was hosted by the ... Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
Breaking Biology News(10 mins):